Madrigal Pharmaceuticals
MDGL
321 hedge funds and large institutions have $7.85B invested in Madrigal Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 109 increasing their positions, 93 reducing their positions, and 32 closing their positions.
125% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 32
111% more call options, than puts
Call options by funds: $346M | Put options by funds: $164M
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
17% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 93
13% more funds holding
Funds holding: 283 → 321 (+38)
11% more capital invested
Capital invested by funds: $7.08B → $7.85B (+$763M)
2.16% more ownership
Funds ownership: 105.25% → 107.4% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$128M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$56.4M |
| 3 |
Morgan Stanley
New York
|
+$54.7M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.5M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$38.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$70.9M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$38.9M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$32.9M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$32.4M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$29.3M |
MDGL Hedge Fund Activity: Q1 2025 in Review
321 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2025, worth a combined $7.85B — up 11% from $7.08B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new MDGL positions and 32 closed out — a net gain of 40 holders — while 109 added to existing stakes and 93 trimmed.
The largest buyer was Holocene Advisors, opening a new position worth an estimated $128M. The largest seller was Fidelity Investments, cutting an estimated $70.9M.
- 321 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2025, up from 283 in Q4 2024.
- Funds reported $7.85B of Madrigal Pharmaceuticals stock for Q1 2025, up 11% quarter-over-quarter.
- 72 funds opened new Madrigal Pharmaceuticals positions in Q1 2025 and 32 closed out, a net change of +40 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2025 was Holocene Advisors, an estimated $128M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2025 was Fidelity Investments, an estimated $70.9M sold.
Based on aggregated 13F filings for Q1 2025.